Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 3Active not recruiting 2Terminated 1Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 185Neoplasms 178Carcinoma, Non-Small-Cell Lung 162Prostatic Neoplasms 114Colorectal Neoplasms 111Lung Neoplasms 94Ovarian Neoplasms 85Neoplasm Metastasis 80Multiple Myeloma 75Pancreatic Neoplasms 73Leukemia, Myeloid, Acute 68Endometrial Neoplasms 53Stomach Neoplasms 49Squamous Cell Carcinoma of Head and Neck 48Melanoma 48Lymphoma 46Glioblastoma 45Recurrence 44Carcinoma, Renal Cell 44Urinary Bladder Neoplasms 42Carcinoma, Hepatocellular 41Brain Neoplasms 41Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Sarcoma 38Lymphoma, Non-Hodgkin 36Leukemia, Lymphocytic, Chronic, B-Cell 36Glioma 36Hematologic Neoplasms 35Small Cell Lung Carcinoma 34Esophageal Neoplasms 33

Interventions

radium Ra 223 dichloride 1peposertib 1avelumab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphatic Metastasis × 30 days × Clear all
NCT04071236 2026-06-05

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡